Provention Bio, A Sanofi Company

This study follows 188 children and adolescents who recently developed type 1 diabetes and completed a prior teplizumab study. Researchers will monitor them for an additional 42 months to check for side effects and track diabetes control measures like insulin use and blood sugar …